-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QLs2pDlPXqjZTWtvac+BS2UmSJWyTsekzTKNPj+05/XZx5la9DT9rhkP6K+egU3+
 RwjK2n4D4pzMfEhmrGg22Q==

<SEC-DOCUMENT>0000012208-07-000027.txt : 20071106
<SEC-HEADER>0000012208-07-000027.hdr.sgml : 20071106
<ACCEPTANCE-DATETIME>20071106171035
ACCESSION NUMBER:		0000012208-07-000027
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20070930
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20071106
DATE AS OF CHANGE:		20071106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO RAD LABORATORIES INC
		CENTRAL INDEX KEY:			0000012208
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				941381833
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-07928
		FILM NUMBER:		071218828

	BUSINESS ADDRESS:	
		STREET 1:		1000 ALFRED NOBEL DR
		CITY:			HERCULES
		STATE:			CA
		ZIP:			94547
		BUSINESS PHONE:		5107247000
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8k3q9302007test.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>UNITED STATES</TITLE>
<META NAME="author" CONTENT="Tom Brida">
<META NAME="date" CONTENT="10/25/2007">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:643.2px"><P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>UNITED STATES</B></P>
<P style="margin:0px" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0px" align=center><B>Washington, D.C. 20549</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>FORM 8-K</B></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>CURRENT REPORT</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px" align=center><B>Date of Report: November 6, 2007</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Date of earliest event reported)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:18.667px" align=center><B>BIO-RAD LABORATORIES, INC.</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Exact name of registrant as specified in its charter)</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:12px; margin:0px"><BR></P>
<P style="margin:0px" align=center><B>Commission File Number: 1-7928</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=360></TD><TD width=7.133></TD><TD width=352.8></TD></TR>
<TR><TD width=360><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD width=352.8><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=360><P style="margin:0px" align=center><B>Delaware</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="margin:0px" align=center><B>94-1381833</B></P>
</TD></TR>
<TR><TD valign=top width=360><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(State or other jurisdiction of</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>incorporation or organization)</B></P>
</TD><TD valign=bottom width=7.133><P style="margin:0px; font-size:10.667px">&nbsp;</P>
</TD><TD valign=top width=352.8><P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(I.R.S. Employer</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>Identification No.)</B></P>
</TD></TR>
</TABLE>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>1000 Alfred Nobel Dr.</B></P>
<P style="margin:0px" align=center><B>Hercules, California 94547</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Address of principal executive offices, including zip code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="margin:0px" align=center><B>(510) 724-7000</B></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px" align=center><B>(Registrant&#146;s telephone number, including area code)</B></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="line-height:10.667px; margin:0px; padding-top:4px; border-top:1px solid #7F0000"><BR></P>
<P style="line-height:10.667px; margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:13.333px; margin:0px; font-size:10.667px">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=562.733></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=562.733><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=565.6></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=565.6><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=616.267></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=616.267><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px; font-size:10.667px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=28.8></TD><TD width=615></TD></TR>
<TR><TD valign=top width=28.8><P style="line-height:13.333px; margin:0px; font-family:Wingdings; font-size:10.667px"><FONT FACE="Wingdings">&#168;</FONT></P>
</TD><TD valign=top width=615><P style="line-height:13.333px; margin:0px; font-size:10.667px"><FONT FACE="Times New Roman">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
<P style="margin:0px; page-break-before:always"><B>&nbsp;</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=285.933></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px" align=justify><B>ITEM 2.02</B></P>
</TD><TD valign=top width=285.933><P style="margin:0px"><B>Results of Operations and Financial Condition</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px">On November 6, 2007, Bio-Rad Laboratories, Inc. announced its results of operations and financial condition as of and for the quarter ended September 30, 2007. &nbsp;A copy of the press release is furnished as Exhibit 99.1 to this report.</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px">In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, shall not be deemed to be &#147;filed&#148; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. </P>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=83.333></TD><TD width=492.667></TD></TR>
<TR><TD valign=top width=83.333><P style="margin:0px"><B>ITEM 9.01</B></P>
</TD><TD valign=top width=492.667><P style="margin:0px"><B>Financial Statements and Exhibits</B></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=60></TD><TD width=24></TD><TD width=497.533></TD></TR>
<TR><TD width=60><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD width=497.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=60><P style="margin:0px"><B>Exhibit</B></P>
<P style="margin:0px"><B>Number&nbsp;</B></P>
</TD><TD valign=bottom width=24><P style="margin:0px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=497.533><P style="margin:0px"><BR></P>
<P style="margin:0px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=60><P style="margin-top:2.2px; margin-bottom:0px" align=right>99.1&nbsp;</P>
</TD><TD valign=bottom width=24><P style="margin-top:2.2px; margin-bottom:0px">&nbsp;</P>
</TD><TD valign=bottom width=497.533><P style="margin-top:2.2px; margin-bottom:0px">Press release of Bio-Rad Laboratories, Inc. dated November 6, 2007</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=center><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; page-break-before:always" align=center><B>SIGNATURES</B></P>
<P style="margin:0px">&nbsp;</P>
<P style="margin:0px">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px">&nbsp;&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=50.867></TD><TD width=136.333></TD><TD width=29.467></TD><TD width=29.467></TD><TD width=4></TD><TD width=253.867></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=287.333 colspan=3><P style="margin:0px">BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=257.867 colspan=2><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=50.867><P style="margin:0px">Date:</P>
</TD><TD style="border-bottom:1px solid #000000" width=136.333><P style="margin:0px">November 6, 2007</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="margin:0px">By:</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=257.867 colspan=2><P style="margin:0px">/s/ Christine A. Tsingos</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Christine A. Tsingos<U> </U></P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=253.867><P style="margin:0px">Vice President, Chief Financial Officer</P>
</TD></TR>
<TR><TD valign=top width=50.867><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=136.333><P style="margin:0px">&nbsp;</P>
</TD><TD valign=top width=29.467><P style="font-size:2pt">&nbsp;</P></TD><TD valign=bottom width=29.467><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=4><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=253.867><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<A NAME="id_11"></A><A NAME="id_12"></A><P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><B>EXHIBIT INDEX</B></P>
<P style="margin:0px">&nbsp;</P>
<TABLE style="font-size:13.333px" cellspacing=0 align=center><TR><TD width=34.2></TD><TD width=28.267></TD><TD width=513.533></TD></TR>
<TR><TD width=34.2><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD width=513.533><P style="margin:0px">&nbsp;</P>
</TD></TR>
<TR><TD style="border-bottom:1px solid #000000" valign=bottom width=34.2><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Exhibit</B></P>
<P style="line-height:12px; margin:0px; font-size:9.333px"><B>Number</B></P>
</TD><TD valign=bottom width=28.267><P style="margin:0px; font-size:9.333px">&nbsp;</P>
</TD><TD style="border-bottom:1px solid #000000" valign=bottom width=513.533><P style="line-height:12px; margin:0px; font-size:9.333px"><B>Description</B></P>
</TD></TR>
<TR><TD valign=top width=34.2><P style="margin:0px">99.1</P>
</TD><TD valign=bottom width=28.267><P style="margin:0px">&nbsp;</P>
</TD><TD valign=bottom width=513.533><P style="margin:0px">Press release of Bio-Rad Laboratories, Inc. dated November 6, 2007</P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>exh991093007.htm
<TEXT>
<!doctype html public "-//IETF//DTD HTML//EN">
<HTML>
<HEAD>
<TITLE>PART 1 &#8211; FINANCIAL INFORMATION</TITLE>
<META NAME="author" CONTENT="Stephanie Trudrung">
<META NAME="date" CONTENT="11/06/2007">
</HEAD>
<BODY style="line-height:12pt; font-family:Times New Roman; font-size:10pt; color:#000000">
<DIV style="width:604.8px"><P style="line-height:17.333px; margin:0px; font-size:14.667px" align=right><B><U>Exhibit 99.1</U></B></P>
<P style="margin:0px" align=right><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="line-height:17.333px; margin:0px; padding-right:43.2px; font-size:14.667px">FOR IMMEDIATE RELEASE</P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px" align=center>BIO-RAD REPORTS THIRD-QUARTER 2007 FINANCIAL RESULTS</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">HERCULES, CA &#150; November 6, 2007 &#150; Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2007.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Third-quarter revenues were<FONT COLOR=#0000FF> </FONT>$339.7 million in 2007, up<FONT COLOR=#0000FF> </FONT>11.5% compared to<FONT COLOR=#0000FF> </FONT>$304.8 million<FONT COLOR=#0000FF> </FONT>reported for the<FONT COLOR=#0000FF> </FONT>same period in 2006.<FONT COLOR=#0000FF> </FONT>These results were driven by continued growth across product areas in both the Life Science and Clinical Diagnostics segments. On a currency-neutral basis, revenues increased 8.0% compared to the same period last year.<FONT COLOR=#FF0000> </FONT>&nbsp;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Net income for the third quarter in 2007 was $28.0 million compared to $23.2 million reported for the<FONT COLOR=#0000FF> </FONT>same period in 2006. &nbsp;Third-quarter net income in 2006 benefited from a pre-tax investment gain of $4.7 million. Net income for the third quarter in 2007 was $1.05 per share, or $1.03 per share on a fully diluted basis, compared to $0.88 and $0.86, respectively, during the same quarter last year. Third-quarter gross margin was 55.4%<FONT COLOR=#0000FF> </FONT>compared to 54.7% in the third quarter last year.<FONT COLOR=#0000FF> </FONT></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Year-to-date revenues grew by 7.6%<FONT COLOR=#0000FF> </FONT>to $1.0 billion compared to the first three quarters in 2006. Normalizing for the impact of currency effects, growth was 3.8%.<FONT COLOR=#0000FF> </FONT>Year-to-date net income for 2007 was<FONT COLOR=#0000FF> </FONT>$80.6 million<FONT COLOR=#0000FF> </FONT>compared to $86.6 million in the same period last year.<FONT COLOR=#0000FF> </FONT>Year-to-date results for the first three quarters in 2006 was favorably impacted by one-time additional revenue of $11.7 million resulting from a licensing settlement agreement reached with bioM&#233;rieux as well as the aforementioned pre-tax investment gain of $4.7 million. Year-to-date gross margin was 55.7% compared to 56.6% in the same period in 2006. &nbsp;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">On a per share basis, year-to-date net income for 2007 was<FONT COLOR=#0000FF> </FONT>$3.03 per share, or $2.96 per share on a fully diluted basis, and $3.29 and $3.22, respectively, for the same period of 2006. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">&#147;We are pleased with the Company&#146;s performance during the quarter and encouraged by the success of new products,&#148; said Norman Schwartz, Bio-Rad President and Chief Executive</P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px" align=center><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-size:14.667px" align=center>&nbsp;(more)</P>
</TD></TR>
</TABLE>
<P style="margin:0px" align=right><P style="padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR>
<BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; padding-right:43.2px; font-size:14.667px">Bio-Rad Reports Third-Quarter 2007 Financial Results</P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Page 2</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Officer. &#147;As we wrap up the year, we will continue to focus on our ongoing businesses and work to integrate the recently acquired DiaMed into Bio-Rad&#146;s organization.&#148;</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:24.667px; margin:0px; font-size:14.667px">Life Science </P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Life Science segment net sales for the quarter were $143.0 million, up 4.1% compared to the same period last year. On a currency-neutral basis, segment sales increased by 1.2%. Performance in the Life Science segment benefited from sales of the new ProteOn<SUP>&#8482;</SUP> XPR36 protein interaction array system as well as the Bio-Plex<SUP>&#174;</SUP> suspension array systems and reagents. Bio-Plex suspension array system sales continue to be boosted by the over 50 new assays that were introduced in 2006. Sales of process chromatography media, particularly &nbsp;CHT<SUP>&#8482;</SUP> Ceramic Hydroxyapatite, were strong as the products continued to gain broad market acceptance. These materials are used in the purification stages in the manufacture of a variety of pharmaceuticals with a particular applicability to monoclonal antibody based medicines. Sales results in this segment were somewhat tempered by continued erosion of BSE (bovine spongifo
rm encephalopathy) testing revenue.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:24.667px; margin:0px; font-size:14.667px">Clinical Diagnostics</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">The Clinical Diagnostics segment reported net sales<FONT COLOR=#0000FF> </FONT>of $193.3 million for the quarter,<FONT COLOR=#0000FF> </FONT>up<FONT COLOR=#0000FF> </FONT>17.6% compared to the third quarter last year,<FONT COLOR=#0000FF> </FONT>or<FONT COLOR=#0000FF> </FONT>13.5% excluding currency effects. These gains were the result of strong sales across all product lines, particularly in quality control, auto-immune, diabetes, and blood virus testing products. During the quarter, Bio-Rad launched a test for syphilis for use on its BioPlex<SUP>&#174;</SUP> 2200 system, a fully-automated random access multiplex testing system that can generate multiple results from a single patient sample. The BioPlex 2200 Syphilis IgG kit simultaneously detects three of the most clinically relevant bacteria that cause syphilis. In September, the Company received FDA clearance to market the MRSASelect<SUP>&#8482;</SUP> test, a chromogenic medium used for the r
apid screening of MRSA (methicillin resistant Staphylococcus aureus). With high sensitivity and specificity as well as rapid and direct identification, the MRSASelect<SUP> </SUP>test can identify MRSA carriers in 24 hours. Also during the quarter, the Company released the Dengue NS1 Ag STRIP rapid test. The test provides early diagnosis of dengue acute infections, a tropical disease transmitted to humans from mosquitoes. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">In the beginning of the fourth quarter of 2007, Bio-Rad completed the purchase of 77.7% of Switzerland-based DiaMed Holding AG for approximately $409 million in cash. DiaMed</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; padding-right:43.2px; font-size:14.667px" align=center>(more)</P>
<P style="margin:0px"><BR></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><P style="padding-left:0px; padding-top:0px; padding-right:43.2px; padding-bottom:0px; width:0px; font-family:Times New Roman; font-size:13.333px; color:#000000; page-break-before:always"><BR>
<BR></P>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; padding-right:43.2px; font-size:14.667px">Bio-Rad Reports Third-Quarter 2007 Financial Results</P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">Page 3</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">develops, manufactures, and markets a complete line of reagents and instruments used in blood typing and screening and has annual sales of approximately $200 million. DiaMed&#146;s results will be included in our consolidated financial statements beginning in the fourth quarter of 2007.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Management will discuss these results in a conference call at 2 PM Pacific Time (5 PM Eastern Time) November 6, 2007. Interested parties can access the call by dialing 800-510-9834 (in the U.S.), or 617-614-3669 (international), access number 71052630. The live webcast can be accessed at http://www.bio-rad.com. A replay of the call will be available at 888-286-8010 (in the U.S.), or 617-801-6888 (international), access number 61856426, for seven days following the call and the webcast can be accessed at http://www.bio-rad.com for 30 days.</P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">About Bio-Rad</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The Company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The Company employs over 6,300 people globally and had revenues of nearly $1.3 billion in 2006. For more information, visit www.bio-rad.com. </P>
<P style="margin:0px"><BR></P>
<P style="line-height:17.333px; margin:0px; font-size:14.667px">This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, &#147;believe,&#148; &#147;expect,&#148; &#147;may,&#148; &#147;will,&#148; &#147;intend,&#148; &#147;estimate,&#148; &#147;continue,&#148; or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the &#147;Risk Factors&#148; in the Company&#146;s public reports filed with the Securities and Exchange Commission, including the Company&#146;s Annual Report on Form 10-K for the fiscal year 
ended December 31, 2006, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. &nbsp;Bio-Rad Laboratories, Inc., disclaims any obligation to update these forward-looking statements. </P>
<P style="line-height:21.333px; margin:0px"><BR></P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">For more information contact:</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Christine Tsingos, Vice President and Chief Financial Officer, or</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Ron Hutton, Treasurer</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">Bio-Rad Laboratories, Inc.</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">510-724-7000</P>
<P style="line-height:21.333px; margin:0px; font-size:14.667px">investor_relations@bio-rad.com </P>
<P style="margin:0px"><BR></P>
</TD></TR>
</TABLE>
<P style="margin:0px"><BR>
<BR></P>
<P style="line-height:21.333px; margin:0px; page-break-before:always"><BR>
<BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=619.2></TD></TR>
<TR><TD valign=top width=619.2><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=right><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=319.333></TD><TD width=74.533></TD><TD width=12></TD><TD width=71.667></TD><TD width=12></TD><TD width=77.667></TD><TD width=12.333></TD><TD width=71></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Income</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>(In thousands, except per share data)</P>
</TD></TR>
<TR><TD valign=top width=650.533 colspan=8><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>(Unaudited)</P>
</TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=158.2 colspan=3><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=161 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=158.2 colspan=3><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Three Months Ended</P>
<P style="line-height:14.667px; margin:0px; font-size:12px" align=center>September 30,</P>
</TD><TD valign=top width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=161 colspan=3><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>Six Months Ended</P>
<P style="line-height:14.667px; margin:0px; font-size:12px" align=center>September 30,</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2007</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2006</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2007</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=center>2006</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net sales</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;339,742&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;304,764&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;1,001,364&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;930,849&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Cost of goods sold</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>151,385&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>137,975&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>443,635&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>403,870&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Gross profit</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>188,357&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>166,789&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>557,729&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>526,979&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Selling, general and administrative expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>117,687&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>105,950&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>344,988&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>316,486&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Product research and development expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>33,145&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>30,988&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>100,680&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>90,050&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Interest expense</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,847&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>8,212&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>23,583&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>24,111&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Foreign exchange (gains) losses, net</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>257&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(293)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(413)</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>959&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Other (income) expense, net</P>
</TD><TD width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(5,687)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(10,514)</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(19,368)</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>(22,809)</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Income before taxes</P>
</TD><TD style="border-top:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>35,108&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>32,446&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>108,259&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>118,182&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Provision for income taxes</P>
</TD><TD style="border-bottom:1px solid #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>7,137&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>9,296&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,620&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>31,568&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Net income</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;27,971&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;23,150&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;80,639&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;86,614&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:2.667px double #000000" width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Basic earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Net income</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;1.05&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.88&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.03&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.29&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Weighted average common shares</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,715&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,407&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,651&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,342&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; font-size:12px">Diluted earnings per share:</P>
</TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Net income</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1.03&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;0.86&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;2.96&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;3.22&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="line-height:14.667px; margin:0px; text-indent:19.2px; font-size:12px">Weighted average common shares</P>
</TD><TD style="border-bottom:2.667px double #000000" width=74.533><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,270&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,971&nbsp;</P>
</TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=77.667><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>27,197&nbsp;</P>
</TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=71><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>26,900&nbsp;</P>
</TD></TR>
<TR><TD width=319.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=74.533><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=71.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12><P style="font-size:2pt">&nbsp;</P></TD><TD width=77.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=12.333><P style="font-size:2pt">&nbsp;</P></TD><TD width=71><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px" align=center><BR>
<BR></P>
<P style="margin:0px; padding-left:-48px; padding-right:-65.333px; font-size:12px; page-break-before:always" align=center>BIO-RAD LABORATORIES, INC</P>
<P style="margin:0px; font-size:12px" align=center>Condensed Consolidated Balance Sheets</P>
<P style="margin:0px; font-size:12px" align=center>(In thousands)</P>
<P style="margin:0px; font-size:12px" align=center>(Unaudited)</P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=415.667></TD><TD width=16.667></TD><TD width=91.4></TD><TD width=17></TD><TD width=90.467></TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="margin:0px; font-size:12px" align=center>September 30,</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="margin:0px; font-size:12px" align=center>December 31,</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=91.4><P style="margin:0px; font-size:12px" align=center>2007</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=90.467><P style="margin:0px; font-size:12px" align=center>2006</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Current assets: </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Cash and cash equivalents</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;472,792&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;223,607&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Short-term investments</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>70,613&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>264,473&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts receivable, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>303,201&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>292,970&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Inventories, net </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>273,575&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>253,045&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="line-height:14.667px; margin:0px; font-size:12px" align=right>99,381&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>95,682&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>1,219,562&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>1,129,777&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Net property, plant and equipment </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>201,608&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>189,627&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Goodwill </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>121,492&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>119,492&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Purchased intangibles, net</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>42,535&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>44,605&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Other assets </P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>127,287&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>112,667&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total assets</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,712,484&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,596,168&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Current liabilities:</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Notes payable and current maturities of long-term debt</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4,907&nbsp;</P>
</TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3,042&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accounts payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>68,102&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>83,411&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Accrued payroll and employee benefits</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>89,769&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>92,101&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Sales, income, and other taxes payable</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>14,885&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>19,949&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; padding-left:19.2px; font-size:12px">Other current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>108,798&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>121,030&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:28.8px; font-size:12px">Total current liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>286,461&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>319,533&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Long-term debt, net of current maturities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>426,141&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>425,625&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Other long-term liabilities</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=91.4><P style="margin:0px; font-size:12px" align=right>53,542&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD width=90.467><P style="margin:0px; font-size:12px" align=right>31,472&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; font-size:12px">Stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>946,340&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>819,538&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="margin:0px; text-indent:38.4px; font-size:12px">Total liabilities and stockholders&#146; equity</P>
</TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=91.4><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;1,712,484&nbsp;</P>
</TD><TD width=17><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=90.467><P style="margin:0px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,596,168&nbsp;</P>
</TD></TR>
<TR><TD valign=top width=415.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=16.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=91.4><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=17><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=90.467><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="line-height:14.667px; margin-top:0px; margin-bottom:6px; font-size:12px">&nbsp;</P>
<P style="margin-top:0px; margin-bottom:6px"><BR>
<BR></P>
<P style="margin-top:0px; margin-bottom:6px; page-break-before:always"><BR></P>
<TABLE style="font-size:13.333px" cellspacing=0><TR><TD width=391.667></TD><TD width=108></TD><TD width=24></TD><TD width=96></TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>BIO-RAD LABORATORIES, INC.</P>
</TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Condensed Consolidated Statements of Cash Flows</P>
</TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(In thousands)</P>
</TD></TR>
<TR><TD valign=top width=619.667 colspan=4><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>(Unaudited) &nbsp;</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=228 colspan=3><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD valign=top width=228 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>Nine Months Ended</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=228 colspan=3><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>September 30,</P>
</TD></TR>
<TR><TD valign=top width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=108><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>2007</P>
</TD><TD valign=top width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" valign=top width=96><P style="line-height:13.333px; margin:0px; font-size:12px" align=center>2006</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from operating activities:</P>
</TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash received from customers</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;1,007,292&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;915,289&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash paid to suppliers and employees</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(880,104)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(789,626)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Interest paid</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(24,008)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(24,528)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Income tax payments</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(32,720)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(9,595)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Litigation settlement</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(3,147)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(45,963)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other operating activities</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>21,116&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>17,789&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash provided by operating activities</P>
</TD><TD style="border-top:1px solid #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>88,429&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>63,366&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from investing activities:</P>
</TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Cash expenditures, net</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(45,938)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(38,079)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Receipt of restricted cash</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>--&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>36,138&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other investing activities</P>
</TD><TD style="border-bottom:1px solid #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>185,996&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(132,102)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Net cash provided by (used in) investing activities</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>140,058&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(134,043)</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash flows from financing activities:</P>
</TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Proceeds from issuance of common stock</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>9,109&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>8,511&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Other financing activities</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>3,481&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>1,051&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Net cash provided by financing activities</P>
</TD><TD style="border-top:1px solid #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>12,590&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>9,562&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Effect of exchange rate changes on cash</P>
</TD><TD style="border-bottom:1px solid #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>8,108&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>2,817&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net increase (decrease) in cash and cash equivalents</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>249,185&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(58,298)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at beginning of period</P>
</TD><TD style="border-bottom:1px solid #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>223,607&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:1px solid #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>296,716&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Cash and cash equivalents at end of period</P>
</TD><TD style="border-bottom:2.667px double #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;472,792&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-bottom:2.667px double #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;238,418&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=499.667 colspan=2><P style="line-height:14.667px; margin:0px; font-size:12px">Reconciliation of net income to net cash provided by operating activities:</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin:0px; padding-left:19.2px; font-size:12px">Net income </P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;80,639&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86,614&nbsp;</P>
</TD></TR>
<TR><TD width=499.667 colspan=2><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjustments to reconcile net income to net cash provided by operating activities:&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Depreciation and amortization</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>43,406&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>40,300&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; text-indent:19.2px; font-size:12px">Changes in working capital</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(43,570)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(29,876)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Litigation settlement</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(3,147)</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>(45,963)</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; padding-left:19.2px; font-size:12px">Other</P>
</TD><TD width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>11,101&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>12,291&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px">Net cash provided by operating activities</P>
</TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=108><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;88,429&nbsp;</P>
</TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD style="border-top:1px solid #000000; border-bottom:2.667px double #000000" width=96><P style="line-height:14.667px; margin-top:0px; margin-bottom:1px; font-size:12px" align=right>$ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;63,366&nbsp;</P>
</TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
<TR><TD width=391.667><P style="font-size:2pt">&nbsp;</P></TD><TD width=108><P style="font-size:2pt">&nbsp;</P></TD><TD width=24><P style="font-size:2pt">&nbsp;</P></TD><TD width=96><P style="font-size:2pt">&nbsp;</P></TD></TR>
</TABLE>
<P style="margin:0px"><BR></P>
<P style="margin:0px"><BR>
<BR></P>
</DIV></BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
